Cassava Sciences shares dropped after the company agreed to a $40 million settlement with the Securities and Exchange ...

Bristol Myers trades higher after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter ...

Alzheimer’s drug developer Cassava Sciences Inc (NASDAQ:SAVA), its founder Remi Barbier, and former Senior VP of Neuroscience ...

Cassava Sciences (NASDAQ:SAVA) has agreed to pay $40M to settle claims by the U.S. Securities and Exchange Commission (SEC) ...

Shares of Cassava Sciences fell 10% in post-market trading on Thursday after the U.S. Securities and Exchange Commission ...

Shares of Cassava Sciences Inc. dropped more than 10% in the extended session Thursday after announcing a settlement with U.S ...

The Securities and Exchange Commission alleged that a researcher for the company manipulated trial data to make its drug ...

Cassava Sciences has agreed to pay $40 million to resolve an investigation into claims it made m | Cassava Sciences has ...

Today, Benzinga 's options scanner spotted 15 uncommon options trades for Cassava Sciences. This isn't normal. The overall ...

Despite the settlement, the Securities and Exchange Commission on Thursday sued Cassava Sciences in the Western District ...

Cassava's financial challenges and data integrity concerns remain critical. Learn why SAVA stock is rated a strong sell given ...

Cassava and former executives were charged Thursday by the SEC with making misleading claims in 2020 about trials for the ...